Chemotherapy – media

First-line use of Roche’s Tecentriq given priority review

US regulators are undertaking a priority review of Roche unit Genentech’s PD-L1 inhibitor Tecentriq, in combination with Avastin and standard chemotherapy for some patients with lung cancer.
- Source: pharmatimes
- 628
- May 9, 2018
Chemotherapy lung cancer Roche Tecentriq
Phase III IMpower131 Study Showed Genentechs TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin and ABRAXANE) Reduced the Risk of Disease Worsening or Death in the Initial Treatment of People with a Type of Advanced Squamous Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMpower131 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ® (atezolizumab) plus chemotherapy (carboplatin and ABRAXANE® [albumin-bound paclitaxel; nab-paclitaxel]) reduced the risk of disease worsening or death (progression-free survival; PFS) compared with chemotherapy alone in the initial (first-line) treatment of people with advanced squamous non-small cell lung cancer (NSCLC). Safety for the TECENTRIQ and chemotherapy combination appeared consistent with the known safety profile of the individual medicines, and no new safety signals were identified with the combination. At this interim analysis a statistically significant overall survival (OS) benefit was not observed and the study will continue as planned. These data will be presented at an upcoming oncology congress.
- Source: cleveland19
- 736
- March 22, 2018
Chemotherapy Clinical Trials Genentech NSCLC oncology
AZ/MSD’s Lynparza wins new CHMP nod

AstraZeneca and MSD’s Lynparza is a step closer to being cleared in Europe as maintenance therapy for some patients with ovarian cancer.
- Source: pharmatimes
- 547
- February 28, 2018
AstraZeneca Chemotherapy MSD New Approvals ovarian cancer
chemoWave app offers patients support during chemotherapy

Following a soft launch last year, the chemoWave disease companion app has now been fully released for chemotherapy patients interested in better managing their care, symptoms, and side effects.
- Source: MobiHealthNews
- 577
- February 11, 2018
Chemotherapy Company Insight digital health mHealth
BMS’ Opdivo and Yervoy combo better than chemo in halting lung cancer progression

Bristol-Myers Squibb has revealed promising data from its ongoing Phase 3 study investigating the efficacy of Opdivo (nivolumab) in combination with Yervoy (ipilimumab) compared to chemotherapy in the first-line treatment of advanced non-small-cell lung cancer (NSCLC) in patients whose cancers have a high tumour mutation burden (TMB), regardless of PD-L1 expression.
- Source: pharmafile
- 556
- February 7, 2018
BMS Chemotherapy NSCLC Opdivo TMB Yervoy
Triple drug treatment combo shows promise in adult leukemia

A triple-drug focused remedy method may provide an efficient new treatment choice for power lymphocytic leukemia (CLL) that reduces the chance for the lengthy-time period unintended effects skilled with chemotherapy and is given for a restricted time, not as a day by day lifetime drug remedy.
- Source: medical-newspaper
- 579
- December 21, 2017
Chemotherapy diabetes Researches triple-drug
Unforeseen new drug target discovered for acute myeloid leukemia

A study has found an unexpected new drug target for acute myeloid leukaemia (AML) that could open new avenues to develop effective treatments against this potentially lethal disease. Researchers from the Wellcome Trust Sanger Institute, the Gurdon Institute and their collaborators show that inhibiting the METTL3 gene destroys human and mouse AML cells without harming non-leukaemic blood cells.
- Source: medicalxpress
- 575
- November 28, 2017
AML blood cancer Chemotherapy leukaemia Researches
12 Questions to Ask BEFORE Saying “Yes” to Chemotherapy Treatment

Conventional doctors have considered chemotherapy treatment and radiation to be the standard of care for so long, they’ve lost sight of the fact that these treatments are causing cancer − not curing it.   Did they somehow miss the fact that these super toxic cancer therapies could be the reason for their repeat customers?
- Source: thetruthaboutcancer
- 668
- November 10, 2017
cancer Chemotherapy

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.